Considering the recent advances in the ovarian cancer’s therapeutic arsenal, CDK4/6 inhibitors are emerging as valuable agents in the setting of different solid malignances, both alone or in combination with other drugs, in agreement with their success in estrogen receptor-positive metastatic breast cancer treatment [59]. This evidence concerns the gene ESR1 and ovarian carcinoma.